Abstract 5004: Application of a comprehensive multi-omic immune profiling strategy achieves superior checkpoint immunotherapy response prediction in lung cancer

Résumé fourni par la source

Abstract Immune checkpoint inhibitors (ICIs) are currently the most effective treatment for late-stage lung cancer. However, most patients fail to mount a durable response, and the mechanisms underlying non-responsiveness remain elusive. Here, we apply a universal omics approach to identify correlates of non-responsiveness to ICIs in lung cancer. In-depth characterization of the plasma proteome was performed using the SomaScan™ platform on pretreatment and longitudinal blood samples from 40 ICI-treated patients, resulting in quantification of 10, 000 unique proteins. In parallel, comprehensive immune phenotyping was achieved with matched pretreatment PBMC for 90% of patients (36/40) through CyTOF™ technology, with a 38-plex panel describing over 150 immune populations in circulation. To enhance clinical outcome predictability of cellular and plasma-based immune relationships, cross-platform data integration was achieved with Stabl, a sparse, reliable omic biomarkers analysis strategy. Stabl identified key predictive features from both CyTOF and SomaScan technology, providing insight into immune deficits present in non-responsive patients. The combined model demonstrated a stronger capability to predict non-response from a pretreatment blood sample (AUROC = 0.79, p-value = 1.7e-2, Mann-Whitney non-parametric test) compared with individual platforms alone. Additionally, this multi-omic strategy is compatible with Imaging Mass Cytometry™ technology, unlocking another layer of clinical investigation via spatial biology. This study ultimately demonstrates both the clinical impact and utility of blood- and imaging-based CyTOF technology and the benefit of combining SomaScan and multi-omic-appropriate analysis approaches. Overall, robust treatment prediction, attributed to biomarker features, provides insights into mechanisms for non-response and highlights the potential for better treatment options in lung cancer. Citation Format: Helen M. McGuire, Natalie Smith, Michael Cohen, Julien Hedou, Grégoire Bellan, Xavier Durand, Erika L. Smith-Mahoney, Julie Alipaz, Jennifer Snyder-Cappione, Brice Gaudilliere, Christina Loh, David King, Michael Hinterberg, Clare Paterson, Barbara Fazekas de St Groth. Application of a comprehensive multi-omic immune profiling strategy achieves superior checkpoint immunotherapy response prediction in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5004.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.